Search

CN-122005637-A - Application of ginseng ganoderma lucidum traditional Chinese medicine composition in medicines for treating hepatocellular carcinoma

CN122005637ACN 122005637 ACN122005637 ACN 122005637ACN-122005637-A

Abstract

The invention discloses application of a ginseng ganoderma lucidum traditional Chinese medicine composition in medicines for treating hepatocellular carcinoma. The invention uses the composition which is prepared by only combining ginseng and lucid ganoderma for preventing and treating the hepatocellular carcinoma, can inhibit proliferation and migration of liver cancer cells, influence the period of the liver cancer cells, lighten inflammation of the liver cancer cells, promote apoptosis of the liver cancer cells and inhibit tumor growth, and provides a new method for preventing and treating the hepatocellular carcinoma.

Inventors

  • Cai Shuangping

Assignees

  • 明远药业有限公司

Dates

Publication Date
20260512
Application Date
20260213

Claims (10)

  1. 1. The application of the ginseng ganoderma lucidum traditional Chinese medicine composition in preparing products for preventing and/or treating hepatocellular carcinoma is that the ginseng ganoderma lucidum traditional Chinese medicine composition is prepared from ginseng and ganoderma lucidum in a mass ratio of 1-3:1-3, and preferably, the ginseng ganoderma lucidum traditional Chinese medicine composition is prepared from ginseng and ganoderma lucidum in a mass ratio of 1:1.
  2. 2. The application of claim 1, wherein the application comprises at least one of: (1) The application in preparing products for inhibiting proliferation and/or migration of liver cancer cells; (2) Application in preparing products for regulating liver cancer cell cycle; (3) The application in preparing products for reducing liver cancer cell inflammation; (4) The application in preparing products for promoting apoptosis of liver cancer cells; (5) The application in preparing products for inhibiting tumor growth.
  3. 3. The use according to claim 2, wherein the liver cancer cell is a HepG2 cell.
  4. 4. The use according to claim 2, wherein the mode of modulating the liver cancer cell cycle is down-regulating the expression of a cell cycle related gene, preferably the gene comprises CCNA, CCNB or CCND.
  5. 5. The use according to claim 1, wherein the product is a medicament.
  6. 6. The use according to any one of claims 1 to 5, wherein PTGS1 or FABP3 is used as a target for the prevention and/or treatment of hepatocellular carcinoma.
  7. 7. The ginseng ganoderma lucidum traditional Chinese medicine composition is characterized by being prepared from ginseng and ganoderma lucidum in a mass ratio of 1-3:1-3, and preferably prepared from ginseng and ganoderma lucidum in a mass ratio of 1:1.
  8. 8. The ginseng ganoderma lucidum traditional Chinese medicine composition according to claim 7, wherein the preparation method of the ginseng ganoderma lucidum traditional Chinese medicine composition comprises the following steps: (1) Weighing ginseng and ganoderma lucidum according to the mass ratio; (2) Pulverizing Ganoderma, decocting in water for three times, mixing decoctions, filtering, and concentrating the filtrate to obtain Ganoderma fluid extract; (3) Drying Ginseng radix, pulverizing, sieving, adding into the Ganoderma extract, mixing, sieving, and drying to obtain Ginseng radix Ganoderma traditional Chinese medicinal composition.
  9. 9. The ginseng ganoderma lucidum traditional Chinese medicine composition according to claim 8, wherein in the step (2), the relative density of the ganoderma lucidum fluid extract is 1.2-1.3 g/cm 3 .
  10. 10. The ginseng ganoderma lucidum traditional Chinese medicine composition according to claim 8, wherein in the step (3), the temperature of ginseng drying is 50-65 ℃, and the mesh number of the sieving is more than or equal to 60 meshes.

Description

Application of ginseng ganoderma lucidum traditional Chinese medicine composition in medicines for treating hepatocellular carcinoma Technical Field The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to application of a ginseng ganoderma lucidum traditional Chinese medicine composition in medicines for treating hepatocellular carcinoma. Background Hepatocellular carcinoma (HCC) is the most common type of Primary Liver Cancer (PLC), and its morbidity and mortality remain significant challenges worldwide, with an estimated 5-year survival rate of only 18%, highlighting the severity of the problem. Over 90% of clinical diagnostic raw PLC cases fall under this category, and the pathogenesis of HCC involves a number of interacting factors, viral infection, liver inflammation, metabolic disorders, genetic mutations, epigenetic changes (affecting gene expression) and immune microenvironment changes. These factors ultimately lead to oncogene inactivation and oncogene activation. However, the exact mechanism driving HCC progression is still poorly understood and there is a lack of effective treatments. Currently HCC is primarily treated by surgery, however half of HCC patients are already at an advanced stage at the time of diagnosis, making liver resection and transplantation impractical. Furthermore, the high recurrence rate and poor prognosis of liver cancer patients remains a major challenge, with HCC patients reported to have a recurrence rate of up to 50% within two years. For advanced HCC, physicians typically employ standard treatment protocols, including chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Although these treatments show significant clinical efficacy, they also have drawbacks. For example, chemotherapeutic agents lack absolute selectivity for cancer cells, and damage normal cells while killing cancer cells. Metabolism of chemotherapy drugs by the liver also increases its burden. Targeted therapy is only applicable to a limited patient population, and tumor cells may develop resistance through various mechanisms (e.g., target mutations and activation of bypass signaling pathways), resulting in reduced therapeutic efficacy. Thus, it is of great interest to find new targets, new drugs, and develop innovative therapies to treat HCC. Disclosure of Invention In order to effectively prevent and treat the HCC, the invention provides the following technical scheme by fully digging the efficacy of the Chinese herbal medicine for treating the HCC. In a first aspect, the invention provides an application of a ginseng ganoderma lucidum traditional Chinese medicine composition in preparing a product for preventing and/or treating hepatocellular carcinoma. Preferably, the ginseng ganoderma lucidum traditional Chinese medicine composition is prepared from ginseng and ganoderma lucidum in a mass ratio of 1-3:1-3; Further, the ginseng ganoderma lucidum traditional Chinese medicine composition is prepared from ginseng and ganoderma lucidum in a mass ratio of 1:1. Preferably, the application comprises at least one of: (1) The application in preparing products for inhibiting proliferation and/or migration of liver cancer cells; (2) Application in preparing products for regulating liver cancer cell cycle; (3) The application in preparing products for reducing liver cancer cell inflammation; (4) The application in preparing products for promoting apoptosis of liver cancer cells; (5) The application in preparing products for inhibiting tumor growth. Further, the inhibition of proliferation of liver cancer cells is achieved by down-regulating the expression of proliferation-related genes. Preferably, the proliferation-related genes include PI3K, PCNA and KI67. Furthermore, the mode of regulating the liver cancer cell cycle is to down regulate the expression of the cell cycle related genes. More preferably, the cell cycle related genes include CCNA, CCNB, and CCND. Further, the reduction of liver cancer cell inflammation is achieved by down-regulating the expression of inflammation-related genes. Preferably, the inflammation-associated genes include ASC, NLRP3 and NF- κB. Further, the promotion of apoptosis of liver cancer cells is achieved by down-regulating the expression of anti-apoptotic genes and/or up-regulating the expression of pro-apoptotic genes. Preferably, the anti-apoptotic genes include Bcl2, bcl-xL, bcl-w, mcl-1, bfl-1 and Brg-1, more preferably Bcl2. Preferably, the pro-apoptotic genes include Bax, bak, bok, bcl-xS, bag, bid, hrk, BNIP3, bimL, EGL, blk and Bad, more preferably Bax. Preferably, the liver cancer cell is a HepG2 cell. Preferably, the product is a medicament. Further, the product also comprises auxiliary materials which are allowed to be added in the medicine. Preferably, PTGS1 or FABP3 is used as a target for preventing and/or treating hepatocellular carcinoma in the application. In a second aspect, the invention prov